Evolus (EOLS)
(Delayed Data from NSDQ)
$11.68 USD
+0.73 (6.67%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $11.66 -0.02 (-0.17%) 5:30 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EOLS 11.68 +0.73(6.67%)
Will EOLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EOLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EOLS
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
EOLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Other News for EOLS
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
Evolus announces submission of PMA to U.S. FDA for two Evolysse products
EOLS Crosses Below Key Moving Average Level
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
Evolus launches Nuceiva or botulinum toxin type A, in Spain